drugset / Trial / NCT01872897

Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients

NCT01872897 ↗

Phase 3 Completed 45 enrolled Reckitt Benckiser Healthcare (UK) Limited
RandomizedCrossoverOpen-labelTreatment

Summary

This study is being conducted to assess the effectiveness of the Compound Sodium Alginate Double Action Chewable Tablets compared to placebo on acidic reflux events into the esophagus in patients diagnosed with Gastroesophageal Reflux Disease (GERD).

Timeline

Start
2013-07-02
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sodium Alginate Double Action Chewable Tablets Unknown 2 unknown —